© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
October 22, 2018
Neuropsychiatric symptoms are now recognized as hallmarks of dementia and are important targets for the development of effective treatments.
October 19, 2018
With more than a dozen available therapies, disease-modification in multiple sclerosis is entering a new era of development.
October 18, 2018
Several agents are currently in development geared at the relief of off-time for patients with Parkinson.
October 17, 2018
Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.
October 16, 2018
Clinical Trial in Progress
A novel mesenchymal stem cell therapy produced intriguing phase II data and has moved into a randomized, pivotal phase III clinical trial.
Physicians offer perspectives on newly approved products to prevent migraine.